Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H20N4 |
| Molecular Weight | 280.3675 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CN(C)C[C@]1([H])CN(C2)C3=NN=C(C=C3)C4=CC=CC=C4
InChI
InChIKey=GTMRUYCIJSNXGB-GASCZTMLSA-N
InChI=1S/C17H20N4/c1-20-9-14-11-21(12-15(14)10-20)17-8-7-16(18-19-17)13-5-3-2-4-6-13/h2-8,14-15H,9-12H2,1H3/t14-,15+
DescriptionCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/17898229 | http://adisinsight.springer.com/drugs/800020139
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/17898229 | http://adisinsight.springer.com/drugs/800020139
A-582941 was found to exhibit high-affinity binding and agonism at alpha-7 nicotinic acetylcholine receptor (α7-nAChR), with acceptable pharmacokinetic properties and excellent distribution to the central nervous system. In vitro and in vivo studies indicated that A-582941 activates signaling pathways known to be involved in cognitive function such as ERK1/2 and CREB phosphorylation. A-582941 enhanced cognitive performance in behavioral assays including the monkey delayed matching-to-sample, rat social recognition, and mouse inhibitory avoidance models that capture domains of working memory, short-term recognition memory, and long-term memory consolidation, respectively. AbbVie is developing α7-nAChR agonists including A-582941 as neuroprotective agents for the treatment of cognitive disorders such as Alzheimer's disease and schizophrenia. Development is at the preclinical stage.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. | 2007 Sep 26 |
|
| The selective alpha7 nicotinic acetylcholine receptor agonist A-582941 activates immediate early genes in limbic regions of the forebrain: Differential effects in the juvenile and adult rat. | 2008 Jun 23 |
|
| Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. | 2008 Spring |
|
| Alpha7 nicotinic acetylcholine receptor activation ameliorates scopolamine-induced behavioural changes in a modified continuous Y-maze task in mice. | 2009 Jan 5 |
|
| In vivo evaluation of alpha7 nicotinic acetylcholine receptor agonists [11C]A-582941 and [11C]A-844606 in mice and conscious monkeys. | 2010 Feb 1 |
|
| α7 Nicotinic receptor agonist enhances cognition in aged 3xTg-AD mice with robust plaques and tangles. | 2014 Feb |
Sample Use Guides
Administration of A-582941 (1 μmol/kg, i.p.) in mouse produced maximal levels in brain (286 ng/g at 0.33 h) that were 11-fold higher than the plasma C max (26 ng/ml at 0.25 h). This distribution ratio was maintained over an 8 h period, as drug cleared from brain and plasma with t 1/2 = 2.5–3.2 h. Similarly, in rat, A-582941 partitions with approximate sixfold higher levels in brain versus plasma after intraperitoneal dosing at 2–20 μmol/kg. Over this dose range, linear pharmacokinetics was observed, with brain C max (normalized to a 1 μmol/kg dose) averaging 363 ng/g and maximum plasma levels of 62 ng/ml.
Route of Administration:
Intraperitoneal
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2MUW0L49BN
Created by
admin on Sat Dec 16 09:19:27 GMT 2023 , Edited by admin on Sat Dec 16 09:19:27 GMT 2023
|
PRIMARY | |||
|
848591-89-9
Created by
admin on Sat Dec 16 09:19:27 GMT 2023 , Edited by admin on Sat Dec 16 09:19:27 GMT 2023
|
PRIMARY | |||
|
1173179-34-4
Created by
admin on Sat Dec 16 09:19:27 GMT 2023 , Edited by admin on Sat Dec 16 09:19:27 GMT 2023
|
ALTERNATIVE | |||
|
44190553
Created by
admin on Sat Dec 16 09:19:27 GMT 2023 , Edited by admin on Sat Dec 16 09:19:27 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
